We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

EKF Diagnostics Showcases STAT-Site WB β-ketone and Glucose Handheld Analyzer Live & in Person at MEDICA 2021

By LabMedica International staff writers
Posted on 15 Nov 2021
Image: STAT-Site® WB analyzer (Photo courtesy of EKF Diagnostics)
Image: STAT-Site® WB analyzer (Photo courtesy of EKF Diagnostics)

EKF Diagnostics (Cardiff, Wales, UK) showcased its recently launched STAT-Site WB β-ketone and glucose handheld analyzer at this year’s MEDICA, the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals.. More than 5,000 exhibitors from 70 countries presented their newest products and ideas at the MEDICA 2021 Trade Fair held in Düsseldorf, Germany from 15-18th November. The event also drew more than 120,000 trade visitors from over 170 countries.

EKF Diagnostics is a global medical manufacturer of point-of-care (POCT) devices and tests for hemoglobin, glycated hemoglobin (HbA1c), glucose and lactate. Its POC analyzers are designed for use within doctors' surgeries, clinics, hospitals and laboratories to provide fast and accurate results at an affordable price. EKF Central Laboratory division manufactures a wide spectrum of reagents for use in hospital laboratories across a broad portfolio of automated and semi-automated analyzers.

MEDICA 2021 became the venue for the first public viewing of the new STAT-Site WB β-ketone and glucose handheld analyzer in Europe since its global launch earlier this year. The STAT-Site WB analyzer from EKF is used for the quantitative determination of β-ketones (Beta-Hydroxybutyrate or β-HB) and glucose in whole blood taken from capillary or venous samples. The STAT-Site WB analyzer uses two different strips to provide results in just ten seconds for β-ketones and five seconds for glucose allowing for clear and comprehensive management of diabetes patients displaying early symptoms of ketosis to be quickly treated and then monitored on a regular basis.

EKF also demonstrated its globally successful PrimeStore MTM (Molecular Transport Medium) molecular transport media that gives the user a “snapshot” in time for that sample by preserving and stabilizing DNA and RNA. PrimeStore MTM was designed and optimized for molecular testing allowing pathogenic samples to be collected, transported, and processed safely and efficiently. The molecular transport medium inactivates infectious biological pathogens including viruses, and gram-positive/negative bacteria whilst preserving and stabilizing labile DNA and RNA for downstream molecular applications.

In addition to PrimeStore MTM, EKF also demonstrated new product innovations relating to the future control of COVID-19, including the COVID-SeroKlir SARS-CoV-2 IgG antibody IVD kit. The Kantaro COVID-SeroKlir kit is a direct ELISA for the quantitative detection of human IgG antibodies to the SARS-CoV-2 virus in serum and plasma (K2-EDTA/Li-Heparin) samples. COVID-SeroKlir is a two-step enzyme-linked immunosorbent assay (ELISA) and can be used by any certified laboratory without the need for proprietary equipment.

Related Links:
EKF Diagnostics 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Total Laboratory Automation Solution
SATLARS Mini T8

Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more